Arca
Skip to content

Acute lymphoblastic leukemia

Drug research and approvals for acute lymphoblastic leukemia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 16, 2026, 470 studies of acute lymphoblastic leukemia are recruiting on ClinicalTrials.gov, Health Canada has authorized 45 drug trials for it since 2013, and FDA has 27 approved and 47 open orphan designations naming it.

  • Recruiting worldwide: 470
  • Trials authorized in Canada: 45
  • FDA orphan approvals: 27
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 470 recruiting on ClinicalTrials.gov ↗

Trials Authorized in Canada

The 10 newest of 45; search them all in Canada trials
Sep 25, 2026A phase 1/2, dose optimization and dose expansion, multicenter, open-label study to evaluate the safety, pharmacokinetics, and efficacy of menin inhibitor…VICRIMENIB (S243249, BN104)ServierPending
May 28, 2026Open label dose-escalation and dose expansion study to evaluate the safety, expansion, persistence and clinical activity of ucart22 {allogeneic engineered…UCART22 / CLLS52CELLECTIS S.A.Closed
Apr 15, 2026A phase 2/3, randomized, open-label, comparison study of mk-1045 versus blinatumomab in participants with relapsed or refractory cd 19+ b-cell acute…MK-1045Merck & Co. (MSD)Ongoing
Apr 1, 2026A global multicenter, open label, randomized phase 3 registrational study of olverembatinib combined with hemotherapy versus investigator’s choice of tki…OLVEREMBATINIB / IMATINIB / DASATINIB / PONATINIBASCENTAGE PHARMA GROUP INC.Pending
Dec 23, 2025Phase II study of subcutaneous blinatumomab plus ponatinib for bcr-abl positive b-cell acute lymphoblastic leukemiaBLINCYTO / ICLUSIGTHE GOVERNORS OF THE UNIVERSITY OF ALBERTAPending
Nov 27, 2025A phase 3, open-label, randomized, controlled trial of subcutaneous versus intravenous blinatumomab in newly diagnosed adults with philadelphia chromosome…SUBCUTANEOUS (SC) BLINATUMOMAB / RITUXIMABAmgenPending
Sep 12, 2025A modular phase I/ii, open-label, multi-center study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy of…AZD4512AstraZeneca Pharmaceuticals LPOngoing
Sep 5, 2025A phase 1b/2 study to investigate the safety, efficacy and pharmacokinetics of administration of subcutaneous (sc) blinatumomab in pediatric participants with…BLINCYTOAmgenPending
Aug 26, 2025Total therapy for infants with acute lymphoblastic leukemia iiZIFTOMENIB / BLINATUMOMAB / VORINOSTAT / BORTEZOMIBPEDIATRIC ONCOLOGY EXPERIMENTAL THERAPEUTIC INVESTIGATOR CONSORTIUMPending
Aug 14, 2025An international pilot study of chemotherapy and tyrosine kinase inhibitors with blinatumomab in patients with newly-diognosed philadelphia chromosome-positive…BLINCYTOCHILDRENS ONCOLOGY GROUPOngoing

FDA Orphan Designations

Approved first, then open designations, newest first; 15 of 74
Aug 1, 2025Phyragotreatment of pediatric patients 1 year of age and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia…Handa Therapeutics, LLCApproved
Nov 8, 2024Aucatzyltreatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)Autolus Incorporated, US subsidiary of Autolus LimitedApproved
Jun 14, 2024Blincytotreatment of CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (ALL) in the consolidation phase…Amgen, Inc.Approved
Mar 19, 2024Iclusigtreatment of adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) in combination…Takeda Pharmaceuticals U.S.A., Inc.Approved
Mar 6, 2024Besponsatreatment of relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients 1…Wyeth Pharmaceuticals, LLCApproved
Dec 5, 2023Phyragotreatment of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) with resistance or intolerance to…Handa Therapeutics, LLCApproved
Oct 1, 2021TecartusTreatment of adult patients with relapsed or refractory B-cell precursor acute lymphomblastic leukemia (ALL)Kite Pharma, Inc.Approved
Jun 30, 2021RylazeAs a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma…Jazz Pharmaceuticals Ireland LimitedApproved
Dec 21, 2018SprycelSPRYCEL (dasatinib) is indicated for the treatment of pediatric patients 1 year of age and older with newly diagnosed Ph+ ALL in…Bristol-Myers Squibb CompanyApproved
Dec 20, 2018Oncaspar; AsparlasASPARLAS is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia in…Servier Pharmaceuticals LLCApproved
Mar 29, 2018BlincytoBLINCYTO® is indicated for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL) in first or second complete remission with…Amgen, Inc.Approved
Aug 30, 2017Kymriah (tisagenlecleucel)Treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or…Novartis Pharmaceuticals CorporationApproved
Aug 17, 2017inotuzumab ozogamicinTreatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL)Wyeth Pharmaceuticals, LLCApproved
Jul 11, 2017Blincytotreatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL) in adults and childrenAmgen, Inc.Approved
Apr 25, 2017XatmepTreatment of pediatric patients with acute lymphoblastic leukemia (ALL) as a component of a combination chemotherapy maintenance regimenSilvergate Pharmaceuticals, Inc.Approved

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.